

REPLY TO ROEMER AND GUERMAZI:

Early biochemical changes on MRI can predict risk of symptomatic progression

Shinjini Kundu^{a,b,1,2}, Beth G. Ashinsky^c, Mustapha Bouhrara^c, Erik B. Dam^d, Shadpour Demehri^e, M. Shifat-E-Rabbi^f, Richard G. Spencer^c, Kenneth L. Urish^{a,g,h,i,j}, and Gustavo K. Rohde^{f,k}

We thank Roemer and Guermazi for their Letter, “Biochemical cartilage changes based on MRI-defined T2 relaxation times do not equal OA detection” (1).

In their comments on our paper (2), the authors (1) raise questions about osteoarthritis (OA) incidence, visual signs of disease on the images, MRI-based scoring systems, and radiomics which we address below.

In ref. 2, we propose a fully automated machine learning technique for discovery of imaging biomarkers in the cartilage of asymptomatic individuals for prediction of future symptomatic OA. We overcome a long-standing limitation of machine learning regarding explainability, by enabling visual recognition of classification biomarkers.

First, regarding OA incidence, the American College of Rheumatology publication (3) cited by the authors (1) recommends diagnosis based on clinical symptoms, radiographs, or laboratory tests, as “no single set of classification criteria could satisfy all circumstances to which the criteria for OA of the knee would be applied. For that reason, the subcommittee elected to design separate sets of classification that might be utilized under different circumstances.” Toward this, our study focuses on individuals with minimal radiographic OA and pain at baseline. We used the Western Ontario and McMaster Universities Arthritis Index (WOMAC) score and Kellgren–Lawrence (KL) score to quantify symptoms and radiographic changes, respectively. The definition of KL ≤ 1 as no “definite” radiographic evidence of OA had been used previously (4) in a study of 4,369 participants and in ref. 5, where radiographic OA was KL ≥ 2 . In the Osteoarthritis Initiative, radiographic knee OA was defined as KL ≥ 2 (6). The

Foundation for the NIH defines knee pain progression as persistent increase in total WOMAC pain score (≥ 9 , 0 to 100 scale) from baseline (7). In our study (2), a change in WOMAC of 23.9 ± 10 was found in progressor group vs. -0.4 ± 2.0 in controls in 3 years ($P < 0.001$). Our metrics are aligned with the goals and scope of the paper, which was to detect imaging biomarkers at baseline that could predict symptom progression in the future and are consistent with prior literature.

Second, regarding visual cartilage signs (8), whole-organ magnetic resonance imaging scores were quantified visually, yet only achieved a prediction accuracy of 60% against our fully automated approach.

Third, regarding MRI-based scoring, the paper by Hunter et al. (9) cited by the authors (1) states that the “MRI definition of knee OA . . . requires further formal testing with regards . . . diagnostic performance (especially in . . . persons with early disease), before they are more widely used.” The paper by Schiphof et al. (10) cited by the authors compares MRI-based changes to radiographic changes at KL ≥ 2 , by which point OA is already clinically apparent by the standard definitions. In contrast, our paper investigates MRI specifically as a modality in the early stages to assess cartilage changes at KL ≤ 1 when symptoms are not yet apparent by clinical definition.

Fourth, we agree that radiomics and feature extraction may help improve prediction of disease incidence and progression of OA, particularly on modalities beyond radiography (11). To this end, the unique contribution of our paper is the ability to quantify discriminating features from cartilage without human input, and their visualization and interpretability.

^aDepartment of Biomedical Engineering, Carnegie Mellon University, Pittsburgh, PA 15213; ^bMedical Scientist Training Program, University of Pittsburgh, Pittsburgh, PA 15213; ^cLaboratory of Clinical Investigation, Magnetic Resonance Imaging and Spectroscopy Section, National Institute on Aging, National Institutes of Health, Baltimore, MD 21224; ^dDepartment of Computer Science, University of Copenhagen, 2100 Copenhagen, Denmark; ^eDepartment of Radiology, The Johns Hopkins Hospital, Baltimore, MD 21287; ^fDepartment of Biomedical Engineering, University of Virginia, Charlottesville, VA 22904; ^gArthritis and Arthroplasty Design Group, The Bone and Joint Center, Magee Womens Hospital of the University of Pittsburgh Medical Center, Pittsburgh, PA 15213; ^hDepartment of Orthopaedic Surgery, University of Pittsburgh, Pittsburgh, PA 15213; ⁱDepartment of Bioengineering, University of Pittsburgh, Pittsburgh, PA 15261; ^jClinical and Translational Science Institute, University of Pittsburgh, Pittsburgh, PA 15261; and ^kDepartment of Electrical and Computer Engineering, University of Virginia, Charlottesville, VA 22904

Author contributions: S.K., B.G.A., M.B., E.B.D., S.D., R.G.S., K.L.U., and G.K.R. designed research; S.K., E.B.D., and M.S.-E.-R. performed research; S.K. and E.B.D. contributed new reagents/analytic tools; S.K., E.B.D., S.D., and M.S.-E.-R. analyzed data; and S.K., B.G.A., M.B., E.B.D., S.D., M.S.-E.-R., R.G.S., K.L.U., and G.K.R. wrote the paper.

The authors declare no competing interest.

Published under the [PNAS license](#).

¹To whom correspondence may be addressed. Email: skundu2@jhmi.edu.

²Present address: Department of Radiology, The Johns Hopkins Hospital, Baltimore, MD 21287.

Published March 8, 2021.

-
- 1 F. W. Roemer, A. Guermazi, Biochemical cartilage changes based on MRI-defined T2 relaxation times do not equal OA detection. *Proc. Natl. Acad. Sci. U.S.A.*, 10.1073/pnas.2023833118 (2021).
 - 2 S. Kundu *et al.*, Enabling early detection of osteoarthritis from presymptomatic cartilage texture maps via transport-based learning. *Proc. Natl. Acad. Sci. U.S.A.* **117**, 24709–24719 (2020).
 - 3 R. Altman *et al.*, Diagnostic and Therapeutic Criteria Committee of the American Rheumatism Association, Development of criteria for the classification and reporting of osteoarthritis. Classification of osteoarthritis of the knee. *Arthritis Rheum.* **29**, 1039–1049 (1986).
 - 4 Y. Wang *et al.*, Knee pain as a predictor of structural progression over 4 years: Data from the Osteoarthritis Initiative, a prospective cohort study. *Arthritis Res. Ther.* **20**, 250 (2018).
 - 5 S. Demehri, N. H. Nejad, F. Roemer, A. Guermazi, Chondroitin sulfate and glucosamine supplementation is associated with higher incidence of radiographic knee osteoarthritis and subsequent knee replacement: Nine years of follow-up data from the osteoarthritis initiative. *Osteoarthritis Cartilage* **24**, S307 (2016).
 - 6 National Institutes of Health, Osteoarthritis Initiative (OAI) study protocol, <https://nda.nih.gov/oai/study-details>. Accessed 7 December 2020.
 - 7 The Biomarkers Consortium, Update of the FNHI Osteoarthritis Biomarker Consortium Project. <https://fnih.org/sites/default/files/final/pdf/bmc-OARSI-Workshop-30APR2015.pdf>. Accessed 7 December 2020.
 - 8 A. Guermazi *et al.*, Prevalence of abnormalities in knees detected by MRI in adults without knee osteoarthritis: Population based observational study (Framingham Osteoarthritis Study). *BMJ* **345**, e5339 (2012).
 - 9 D. J. Hunter *et al.*; OARSI OA Imaging Working Group, Definition of osteoarthritis on MRI: Results of a Delphi exercise. *Osteoarthritis Cartilage* **19**, 963–969 (2011).
 - 10 D. Schiphof *et al.*, Sensitivity and associations with pain and body weight of an MRI definition of knee osteoarthritis compared with radiographic Kellgren and Lawrence criteria: A population-based study in middle-aged females. *Osteoarthritis Cartilage* **22**, 440–446 (2014).
 - 11 F. W. Roemer *et al.*, State of the art: Imaging of osteoarthritis—Revisited 2020. *Radiology* **296**, 5–21 (2020).